Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
01:31pm, Friday, 29'th Aug 2025
AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 27'th Aug 2025
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings
01:40pm, Tuesday, 05'th Aug 2025
Axsome Therapeutics, Inc. AXSM reported better-than-expected second-quarter financial results on Monday.
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
12:41pm, Tuesday, 05'th Aug 2025
Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.
Axsome Therapeutics, Inc. (AXSM) Q2 2025 Earnings Call Transcript
02:50pm, Monday, 04'th Aug 2025
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Ari Maizel - Chief Commercial Officer Darren Opland - Corporate Participant Her
Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings
10:31am, Monday, 04'th Aug 2025
While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to
Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates
09:11am, Monday, 04'th Aug 2025
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $1.24 per share a year ago.
Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
07:00am, Monday, 04'th Aug 2025
Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY ® 2Q 2025 net product sales of $119.6 million, representing growth of 84%
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Monday, 28'th Jul 2025
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axsome: Some Recent Setbacks, Some Recent Wins -- Still A Buy
01:46pm, Friday, 25'th Jul 2025
Axsome's valuation is driven by its promising pipeline, with Auvelity as a proven commercial success and Symbravo and AXS-12 showing solid potential. Recent setbacks include the FDA's refusal to file
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now
05:51am, Thursday, 24'th Jul 2025
Should you invest in stocks right now? Some might be hesitant to do so because of the volatility broader equities have faced this year.
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
07:30am, Monday, 21'st Jul 2025
Comprehensive review of broad pipeline targeting Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4
07:00am, Wednesday, 09'th Jul 2025
NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
07:00am, Friday, 20'th Jun 2025
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is
